Influenza Medications Market Analysis

Influenza Medications Market Analysis

The market based on drug type is bifurcated into antiviral drugs, antihistamines, analgesics, and antipyretics. The antiviral drugs segment generated USD 520.3 million in 2023 and will witness growth at 3.4% CAGR during 2024-2032. Antibiotics are considered the mainstay of treatment for influenza infections. These are important in the management and treatment of influenza, as their direct aim is to reduce the severity and duration of viral infection. The effectiveness in the treatment of influenza has led to their widespread use, especially during influenza season.  Moreover, improved development of new antiviral drugs and better safety profile have further enhanced the product uptake.

To get key market trends

  Download Free Sample

Based on influenza type, the influenza medications market size from the influenza A segment was valued at over USD 704 million in 2023 and is expected to reach USD 897.4 million by 2032. Influenza A viruses are responsible for most influenza outbreaks at times and can cause severe illness compared to influenza B viruses. This virus circulates extensively and is known to cause significant morbidity and mortality, resulting in increased demand for influenza A vaccines and prevention. The widespread accessibility and prescription of antiviral drugs and the rising usage of influenza vaccines to prevent influenza A will contribute to the segment growth.

In terms of age group, the influenza medications market from the adults segment is expected to depict 3% CAGR from 2024 – 2032. Adults usually experience higher rates of influenza incidence compared to pediatric and geriatric populations. They are exposed to influenza viruses in social settings, workplaces, and public spaces, leading to increased susceptibility to infection. They also experience severe symptoms compared to children, subsequently requiring more intensive medication and care. Thus, the higher incidence rates along with increased severity of the disorder will drive significant demand for influenza medications among adults.

Based on type, the influenza medications market from the branded segment was valued at USD 755 million in 2023. Branded products are often associated with established pharmaceutical companies with a reputation for quality, efficacy, and safety. These drugs typically result from extensive R&D efforts, including preclinical studies, clinical trials, and regulatory approvals. Additionally, healthcare professionals frequently prescribe branded medicines, contributing to the segment growth.
 

Based on route of administration, the oral segment is expected to reach over USD 1 billion by 2032. The oral route facilitates dose adjustment and convenience, making it suitable for a wide range of patients, including children and the elderly. Moreover, oral medications tend to be more cost-effective compared to other delivery methods, such as intravenous or inhaled drugs, due to lower manufacturing and delivery costs. This affordability is making these medications attractive to patients and healthcare systems.
 

Influenza medications market from the prescription medication segment was valued at USD 708.9 million in 2023 and will strike a 2.6% CAGR through 2032. Prescription drugs are more potent and specific in targeting the influenza virus, making them more effective compared to alternatives.  The potential for severe complications from influenza, particularly in high-risk populations, such as the elderly, young children and individuals with underlying health conditions will drive the demand for potential prescription drugs for providing effective treatment and reduced risk of complications. The dominance of prescription drugs to support the health system and ensure optimal outcomes for patients will favor the product uptake.
 

Based on distribution channel, the influenza medications market value from the hospital pharmacies segment is predicted to generate USD 619.7 million by 2032. Hospitals serve as the primary point for patient care with a high volume of patients compared to other healthcare settings for catering to a greater demand for influenza medications. Hospital pharmacies are staffed by druggists with clinical expertise who work closely with healthcare providers to assure accurate and safe medication management for individuals. The strict regulation and control over the distribution and usage of drugs is also making these channels the preferred and regulated source for these medications.

North America influenza medications market size may reach USD 548.7 million by 2032 attributed to the significant burden of influenza infections annually. Factors, such as population density, international travel, and seasonal variations are contributing to the widespread transmission of influenza viruses, leading to a high demand for influenza medicines. The well-developed healthcare infrastructure with advanced medical facilities, including clinics, hospitals, and pharmacies will further propel the regional market growth.